文献速递牙体牙髓病

细胞再生牙髓治疗根尖周病变的随机对照I/II期临床试验

Cell-Based Regenerative Endodontics for Treatment of Periapical Lesions: A Randomized, Controlled Phase I/II Clinical Trial.
PubMed 文献 · J Dent Res · 2020-03-23

一项随机对照I/II期试验纳入36例成熟恒牙根尖周病变患者,比较异体脐带间充质干细胞封装于血浆来源生物材料行再生牙髓治疗(REP)与传统根管治疗(ENDO)的安全性和疗效。12个月随访两组均无不良事件、临床有效率100%,REP组灌注单位百分比从60.6%升至78.1%,冷热和电活力测试阳性反应均提高。

要点

  • 异体脐带间充质干细胞封装于血浆来源生物材料用于REP安全且临床有效
  • REP组12个月激光多普勒灌注单位百分比从60.6%升至78.1%
  • REP组牙髓活力测试阳性率提高:冷6%→56%、热0%→28%、电17%→50%

核心结论

  • 异体脐带间充质干细胞封装于血浆来源生物材料用于再生牙髓治疗,在成熟恒牙根尖周病变中显示安全性和临床有效性。
  • REP组在12个月随访时牙髓灌注和活力测试阳性反应均较基线提高。

研究设计与样本

  • 随机对照I/II期临床试验,纳入36例有牙髓坏死和根尖周炎的成熟切牙、尖牙或下颌前磨牙患者。
  • 患者随机等量分配至实验组(REP)或常规根管治疗组(ENDO)。
  • 首次就诊行开髓和根管机械预备,氢氧化钙封药并封闭窝洞,3周后按分组方案治疗。
  • 临床随访在6个月和12个月进行;分类变量用Fisher精确检验,定量变量用Mann-Whitney检验。

主要发现

  • 12个月随访时两组均未报告不良事件,临床有效率均为100%。
  • REP组激光多普勒血流仪测得的灌注单位百分比从基线60.6%增至12个月78.1%。
  • REP组12个月随访时牙髓活力测试阳性反应增加:冷测试从6%升至56%,热测试从0%升至28%,电测试从17%升至50%。

临床怎么用

  • 对于成熟恒牙伴根尖周病变,可考虑在常规根管预备和氢氧化钙封药后,采用异体脐带间充质干细胞封装于血浆来源生物材料行再生牙髓治疗。
  • 术后6个月和12个月随访时应评估激光多普勒灌注单位和牙髓活力测试(冷、热、电)变化。

局限性

  • 原文未明确报告样本量计算、盲法设置和统计学效能等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A randomized controlled phase I/II clinical trial was designed to evaluate the safety and efficacy of encapsulated human umbilical cord mesenchymal stem cells in a plasma-derived biomaterial for regenerative endodontic procedures (REPs) in mature permanent teeth with apical lesions. The trial included 36 patients with mature incisors, canines, or mandibular premolars showing pulp necrosis and apical periodontitis. Patients were randomly and equally allocated between experimental (REP) or conventional root canal treatment (ENDO) groups. On the first visit, cavity access and mechanical preparation of the root canal were performed. Calcium hydroxide medication was used, and the cavity was sealed. Three weeks later, patients were treated following their assigned protocol of ENDO or REP. Clinical follow-up examinations were performed at 6 and 12 mo. Categorical variables were evaluated by Fisher's exact test. Quantitative variables were compared using the Mann-Whitney test. The evolution over time of the percentage of perfusion units and the dimensions of lesion and cortical compromise were explored. After the 12-mo follow-up, no adverse events were reported, and the patients showed 100% clinical efficacy in both groups. Interestingly, in the REP group, the perfusion unit percentage measured by laser Doppler flowmetry revealed an increase from 60.6% to 78.1% between baseline and 12-mo follow-up. Sensitivity tests revealed an increase of the positive pulp response in the REP group at 12-mo follow-up (from 6% to 56% on the cold test, from 0% to 28% on the hot test, and from 17% to 50% on the electrical test). We present the first clinical safety and efficacy evidence of the endodontic use of allogenic umbilical cord mesenchymal stem cells encapsulated in a plasma-derived biomaterial. The innovative approach, based on biological principles that promote dentin-pulp regeneration, presents a promising alternative for the treatment of periapical pathology (ClinicalTrials.gov NCT03102879).

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Brizuela C, Meza G, Urrejola D, et al. Cell-Based Regenerative Endodontics for Treatment of Periapical Lesions: A Randomized, Controlled Phase I/II Clinical Trial. J Dent Res. 2020. PMID: 32202965. doi:10.1177/0022034520913242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。